MedTrace Logo

Composition for Treating Spermatogenesis and Semen Disorders / FPT-20

NCT05399212 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-16

No results posted yet for this study

Summary

Research to develop a new, natural-derived formulation that eliminates inflammatory tissue and regenerates new tissue of the lobules, epithelium of the tubules, and connective tissue surrounding the seminiferous tubules in the testes. It restores Leydig cells and Sertoli cells' function (because the inflamed testicles were unable to perform spermatogenesis).

Conditions

  • Spermatogenesis and Semen Disorders

Interventions

DRUG

FPT-20

FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.

Sponsors & Collaborators

  • TRAN MINH DUC, MD

    collaborator UNKNOWN

  • Trieu, Nguyen Thi, M.D.

    lead INDIV

Principal Investigators

  • Nguyen Thi Trieu, Dr. · Trieu, Nguyen Thi, M.D.

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2022-05-20
Completion
2022-05-20
FDA Drug
Yes

Countries

  • United States
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05399212 on ClinicalTrials.gov